drugset / Trial / NCT00345319

Purified Rabies Vaccine for Human Use (Chick-embryo Cell)

NCT00345319

Phase 3 Completed 630 enrolled Novartis Vaccines
RandomizedParallel-groupSingle-blindPrevention

Summary

Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.

Timeline

Start
2006-03
Primary completion
2006-05
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rabies vaccine Vaccine

Indications